Ilyang Pharm (007570) — Cash Flow Quality Index
Latest as of June 2025:
3.92x
Ilyang Pharm (007570) has a Cash Flow Quality Index of 3.92x as of June 2025. Operating cash flow of ₩2.26 Billion exceeds net income of ₩576.52 Million, indicating high earnings quality where cash backs reported profits. Explore debt repayment capacity of Ilyang Pharm to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
3.92x
Operating CF / Net Income
Operating Cash Flow
₩2.26 Billion
KRW
Net Income
₩576.52 Million
KRW
Data as of
Jun 2025
Most recent filing
Ilyang Pharm Cash Flow Quality Index (2003–2024)
Historical Cash Flow Quality Index for Ilyang Pharm across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 007570 operating cash flow.
Annual Cash Flow Quality Index for Ilyang Pharm (2003–2024)
Year-by-year earnings quality comparison for Ilyang Pharm.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.55x | ₩5.61 Billion | ₩10.26 Billion | ▼ -52.7% |
| 2023 | 1.16x | ₩13.34 Billion | ₩11.52 Billion | ▼ -25.6% |
| 2022 | 1.56x | ₩29.94 Billion | ₩19.24 Billion | ▼ -66.6% |
| 2021 | 4.66x | ₩67.02 Billion | ₩14.38 Billion | ▼ -11.8% |
| 2020 | 5.28x | ₩57.48 Billion | ₩10.88 Billion | ▲ +45.8% |
| 2019 | 3.62x | ₩36.19 Billion | ₩9.98 Billion | ▼ -24.4% |
| 2017 | 4.79x | ₩30.03 Billion | ₩6.26 Billion | ▲ +4.9% |
| 2016 | 4.57x | ₩26.98 Billion | ₩5.91 Billion | ▼ -50.0% |
| 2015 | 9.13x | ₩40.27 Billion | ₩4.41 Billion | ▲ +1292.2% |
| 2013 | -0.77x | ₩-3.04 Billion | ₩3.96 Billion | ▼ -108.5% |
| 2003 | 9.01x | ₩10.08 Billion | ₩1.12 Billion | — |
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.